



Recommended algorithm for monitoring & management with OADs in patients admitted to hospital during these times by Ministry of Health & Family Welfare, Government of India.



* Consult Endocrinologist/physician at earliest

Guidance on the use of oral glucose lowering agents (Oral-GLAs)



Relatively Safe	Caution	Stop if disease severity increases. Do not initiate if patients is not on these drugs
DPP-4 inhibitors	Metformin: Risk of lactic acidosis if moderately to severely ill with hemodynamic instability or hypoxia	SGLT-2 Inhibitors: Increase risk of dehydration and euglycemic ketoacidosis
Vidagliptin/ Teneligliptin/ Sitagliptin/ Linagliptin	Sulfonylureas: Risk of hypoglycemia if oral intake is poor or with concomitant use of insulin therapy	Pioglitazone: Risk of fluid retention and edema; contraindicated in cardiac or hepatic dysfunction

Abbreviations: ADN: After dinner; BBF: Before breakfast, ABF: After Breakfast; BDN: Before dinner, BL: Before lunch, AL : After Lunch; BG: Blood glucose; CBG: Capillary blood glucose;

Clinical guidance on diagnosis and management of diabetes in COVID-19 patient management facility (version 2.0). Available at <https://www.mohfw.gov.in/pdf/ClinicalGuidanceonDiagnosisandManagementofDiabetesatCOVID19PatientManagementfacility.pdf>. Last accessed on 16th June 2021.

